BACKGROUND: Discontinuation of bisphosphonates (BP) or a "drug holiday" after several years of treatment is increasingly common. However, the association of drug holiday duration with future fracture risk is unclear. OBJECTIVES: We evaluated the rate of fracture in relation to various lengths of drug holidays among women receiving long-term BP therapy. RESEARCH DESIGN: Observational cohort study using US Medicare data 2006-2016. Incidence rates (IRs) and Cox proportional hazards models were used to evaluate the rate and adjusted hazard ratios (aHRs) controlling for potential confounders. SUBJECTS: Women aged 65 years and above enrolled in fee-for-service Medicare who had been adherent (≥80%) to alendronate, risedronate, or zoledronate for ≥3 years. MEASURES: Hip, humerus, distal forearm, and clinical vertebral fracture. RESULTS: Among 81,427 eligible women observed for a median (interquartile range) of 4.0 (2.5, 5.3) years, 28% of women underwent a drug holiday. In the alendronate cohort (73% overall), the IR of hip fracture among women who discontinued BP for >2 years was 13.2 per 1000 person-years. Risk was increased (aHR=1.3, 1.1-1.4) versus continuing therapy (IR=8.8, referent). Rates were elevated for humerus fracture with discontinuation >2 years (aHR=1.3, 1.1-1.66) and for clinical vertebral fracture with discontinuation >2 years (aHR=1.2, 1.1-1.4). Results were similar for risedronate, zoledronate, and ibandronate for hip and clinical vertebral fracture. CONCLUSION: Discontinuing alendronate beyond 2 years was associated with increased risk of hip, humerus, and clinical vertebral fractures.
BACKGROUND: Discontinuation of bisphosphonates (BP) or a "drug holiday" after several years of treatment is increasingly common. However, the association of drug holiday duration with future fracture risk is unclear. OBJECTIVES: We evaluated the rate of fracture in relation to various lengths of drug holidays among women receiving long-term BP therapy. RESEARCH DESIGN: Observational cohort study using US Medicare data 2006-2016. Incidence rates (IRs) and Cox proportional hazards models were used to evaluate the rate and adjusted hazard ratios (aHRs) controlling for potential confounders. SUBJECTS:Women aged 65 years and above enrolled in fee-for-service Medicare who had been adherent (≥80%) to alendronate, risedronate, or zoledronate for ≥3 years. MEASURES: Hip, humerus, distal forearm, and clinical vertebral fracture. RESULTS: Among 81,427 eligible women observed for a median (interquartile range) of 4.0 (2.5, 5.3) years, 28% of women underwent a drug holiday. In the alendronate cohort (73% overall), the IR of hip fracture among women who discontinued BP for >2 years was 13.2 per 1000 person-years. Risk was increased (aHR=1.3, 1.1-1.4) versus continuing therapy (IR=8.8, referent). Rates were elevated for humerus fracture with discontinuation >2 years (aHR=1.3, 1.1-1.66) and for clinical vertebral fracture with discontinuation >2 years (aHR=1.2, 1.1-1.4). Results were similar for risedronate, zoledronate, and ibandronate for hip and clinical vertebral fracture. CONCLUSION: Discontinuing alendronate beyond 2 years was associated with increased risk of hip, humerus, and clinical vertebral fractures.
Authors: Jeffrey R Curtis; Huifeng Yun; Jeff L Lange; Robert Matthews; Pradeep Sharma; Kenneth G Saag; Elizabeth Delzell Journal: Arthritis Care Res (Hoboken) Date: 2012-12 Impact factor: 4.794
Authors: Nicole C Wright; Shanette G Daigle; Mary E Melton; Elizabeth S Delzell; Akhila Balasubramanian; Jeffrey R Curtis Journal: J Bone Miner Res Date: 2019-08-05 Impact factor: 6.741
Authors: Annette L Adams; John L Adams; Marsha A Raebel; Beth T Tang; Jennifer L Kuntz; Vinutha Vijayadeva; Elizabeth A McGlynn; Wendolyn S Gozansky Journal: J Bone Miner Res Date: 2018-05-24 Impact factor: 6.741
Authors: Ann V Schwartz; Douglas C Bauer; Steven R Cummings; Jane A Cauley; Kristine E Ensrud; Lisa Palermo; Robert B Wallace; Marc C Hochberg; Adrianne C Feldstein; Antonio Lombardi; Dennis M Black Journal: J Bone Miner Res Date: 2010-05 Impact factor: 6.741
Authors: Douglas C Bauer; Ann Schwartz; Lisa Palermo; Jane Cauley; Marc Hochberg; Art Santora; Steven R Cummings; Dennis M Black Journal: JAMA Intern Med Date: 2014-07 Impact factor: 21.873
Authors: Jeffrey R Curtis; Joseph C Larson; Elizabeth Delzell; Maurice Alan Brookhart; Suzanne M Cadarette; Rowan Chlebowski; Suzanne Judd; Monika Safford; Daniel H Solomon; Andrea Z Lacroix Journal: Med Care Date: 2011-05 Impact factor: 2.983
Authors: Jeffrey R Curtis; Amy S Mudano; Daniel H Solomon; Juan Xi; Mary Elkins Melton; Kenneth G Saag Journal: Med Care Date: 2009-01 Impact factor: 2.983
Authors: Beatrice J Edwards; Mrinal Gounder; June M McKoy; Ian Boyd; Mathew Farrugia; Cesar Migliorati; Robert Marx; Salvatore Ruggiero; Meletios Dimopoulos; Dennis W Raisch; Seema Singhal; Ken Carson; Eniola Obadina; Steve Trifilio; Dennis West; Jayesh Mehta; Charles L Bennett Journal: Lancet Oncol Date: 2008-12 Impact factor: 41.316
Authors: Dennis M Black; Ian R Reid; Steven Boonen; Christina Bucci-Rechtweg; Jane A Cauley; Felicia Cosman; Steven R Cummings; Trisha F Hue; Kurt Lippuner; Peter Lakatos; Ping Chung Leung; Zulema Man; Ruvie Lou Maria Martinez; Monique Tan; Mary Ellen Ruzycky; Guoqin Su; Richard Eastell Journal: J Bone Miner Res Date: 2012-02 Impact factor: 6.741
Authors: Monika A Izano; Joan C Lo; Annette L Adams; Bruce Ettinger; Susan M Ott; Malini Chandra; Rita L Hui; Fang Niu; Bonnie H Li; Romain S Neugebauer Journal: JAMA Netw Open Date: 2020-12-01